Search results for "Quotation"

showing 10 items of 18815 documents

Treg cells as potential cellular targets for functionalized nanoparticles in cancer therapy.

2016

Treg cell-mediated immune suppression appears to represent a significant barrier to effective anticancer immune responses and their inactivation or removal is viewed as a potential therapeutic approach. Although suitable tools for selective Treg cell manipulation in man are missing, their number and function can be altered by a number of drugs and biologicals and by reprogramming tumor-infiltrating antigen presenting cells. Nanoparticles offer exceptional new options in drug and gene delivery by prolonging the circulation time of their cargo, protecting it from degradation and promoting its local accumulation in cells and tissues. In tumor therapy, the use of nanoparticles is expected to o…

0301 basic medicineDrugmedia_common.quotation_subjectBiomedical EngineeringMedicine (miscellaneous)Antigen-Presenting CellsBioengineeringDevelopmentBiologyGene deliveryT-Lymphocytes Regulatory03 medical and health sciences0302 clinical medicineImmune systemNeoplasmsAnimalsHumansGeneral Materials ScienceAntigen-presenting cellMelanomamedia_common030104 developmental biologyImmunologyDrug deliveryCancer researchNanomedicineNanoparticlesImmunotherapyReprogrammingFunction (biology)030215 immunologyNanomedicine (London, England)
researchProduct

A lipidomic cell-based assay for studying drug-induced phospholipidosis and steatosis

2017

Phospholipidosis and steatosis are two toxic effects, which course with overaccumulation of different classes of lipids in the liver. MS-based lipidomics has become a powerful tool for the comprehensive determination of lipids. LC-MS lipid profiling of HepG2 cells is proposed as an in vitro assay to study and anticipate phospholipidosis and steatosis. Cells with and without pre-incubation with a mixture of free fatty acids (FFA) (i.e., oleic and palmitic) were exposed to a set of well-known steatogenic and phospholipidogenic compounds. The use of FFA pre-loading accelerated the accumulation of phospholipids thus leading to a better discrimination of phospholipidosis, and magnified the lipid…

0301 basic medicineDrugmedia_common.quotation_subjectClinical BiochemistryLipidosesModels BiologicalBiochemistryMass SpectrometryAnalytical Chemistry03 medical and health scienceschemistry.chemical_compound0302 clinical medicineLipidomicsmedicineHumansPhosphatidylserinesLeast-Squares AnalysisPhospholipidsmedia_commonPhospholipidosisChemistryComputational BiologyHep G2 Cellsmedicine.diseaseIn vitroFatty LiverOleic acid030104 developmental biologyBiochemistry030220 oncology & carcinogenesislipids (amino acids peptides and proteins)Chemical and Drug Induced Liver InjurySteatosisIntracellularChromatography LiquidELECTROPHORESIS
researchProduct

Overview of key molecular and pharmacological targets for diabetes and associated diseases

2021

Diabetes epidemiological quantities are demonstrating one of the most important communities' health worries. The essential diabetic difficulties are including cardiomyopathy, nephropathy, inflammation, and retinopathy. Despite developments in glucose decreasing treatments and drugs, these diabetic complications are still ineffectively reversed or prohibited. Several signaling and molecular pathways are vital targets in the new therapies of diabetes. This review assesses the newest researches about the key molecules and signaling pathways as targets of molecular pharmacology in diabetes and diseases related to it for better treatment based on molecular sciences. The disease is not cured by c…

0301 basic medicineDrugmedia_common.quotation_subjectDiseaseType 2 diabetesBioinformatics030226 pharmacology & pharmacyGeneral Biochemistry Genetics and Molecular BiologyNephropathyDiabetes Complications03 medical and health sciences0302 clinical medicineDiabetes mellitusDrug DiscoveryDiabetes MellitusAnimalsHumansHypoglycemic AgentsMedicineMolecular Targeted TherapyPharmacology & PharmacyGeneral Pharmacology Toxicology and Pharmaceuticsmedia_commonGlycemicbusiness.industry0601 Biochemistry and Cell Biology 1115 Pharmacology and Pharmaceutical SciencesGeneral MedicineMolecular PharmacologyA300medicine.diseaseHuman genetics030104 developmental biologybusinessSignal Transduction
researchProduct

Upgrading HepG2 cells with adenoviral vectors that encode drug-metabolizing enzymes: application for drug hepatotoxicity testing.

2016

Drug attrition rates due to hepatotoxicity are an important safety issue considered in drug development. The HepG2 hepatoma cell line is currently being used for drug-induced hepatotoxicity evaluations, but its expression of drug-metabolizing enzymes is poor compared with hepatocytes. Different approaches have been proposed to upgrade HepG2 cells for more reliable drug-induced liver injury predictions. Areas covered: We describe the advantages and limitations of HepG2 cells transduced with adenoviral vectors that encode drug-metabolizing enzymes for safety risk assessments of bioactivable compounds. Adenoviral transduction facilitates efficient and controlled delivery of multiple drug-metab…

0301 basic medicineDrugmedia_common.quotation_subjectGenetic VectorsBiologyPharmacologyToxicologyENCODERisk AssessmentAdenoviridae03 medical and health sciencesToxicity TestsmedicineAnimalsHumansmedia_commonPharmacologyLiver injurychemistry.chemical_classificationReproducibility of ResultsGeneral MedicineHep G2 Cellsmedicine.disease030104 developmental biologyEnzymemedicine.anatomical_structureDrug developmentchemistryPharmaceutical PreparationsHepg2 cellsHepatocyteDrug DesignCancer researchHepatocytesChemical and Drug Induced Liver InjuryDrug metabolismExpert opinion on drug metabolismtoxicology
researchProduct

Myotonic dystrophy type 1 drug development: A pipeline toward the market

2021

Highlights • Myotonic dystrophy, a neuromuscular disease, affects at least around half a million people worldwide. • Close to two dozen preclinical and clinical drug development programs active. • Drugs encompass new chemical entities, repurposing, oligonucleotide, and gene therapy. • Tideglusib, mexiletine, and metformin are close to reaching marketing authorization.

0301 basic medicineDrugmedia_common.quotation_subjectMyotonic dystrophyDiseaseBioinformaticsMarketing authorizationMyotonic dystrophy03 medical and health sciences0302 clinical medicineGene therapyDrug DevelopmentDrug DiscoveryMedicineAnimalsHumansAntisense oligonucleotideRepurposingmedia_commonPharmacologybusiness.industryRepurposing drugmedicine.diseaseClinical trialClinical trialDrug repositioning030104 developmental biologyDrug development030220 oncology & carcinogenesisbusinessPost-Screen (Grey)Drug Discovery Today
researchProduct

Advances in drug-induced cholestasis: Clinical perspectives, potential mechanisms and in vitro systems

2018

Despite growing research, drug-induced liver injury (DILI) remains a serious issue of increasing importance to the medical community that challenges health systems, pharmaceutical industries and drug regulatory agencies. Drug-induced cholestasis (DIC) represents a frequent manifestation of DILI in humans, which is characterised by an impaired canalicular bile flow resulting in a detrimental accumulation of bile constituents in blood and tissues. From a clinical point of view, cholestatic DILI generates a wide spectrum of presentations and can be a diagnostic challenge. The drug classes mostly associated with DIC are anti-infectious, anti-diabetic, anti-inflammatory, psychotropic and cardiov…

0301 basic medicineDrugmedicine.drug_classmedia_common.quotation_subjectReceptors Cytoplasmic and NuclearMiscellaneous DrugsIn Vitro TechniquesToxicologyBioinformaticsBile flow03 medical and health sciences0302 clinical medicineCholestasismedicineAnimalsBileHumansDrug induced cholestasismedia_commonCholestasisPolymorphism GeneticBile acidbusiness.industryMembrane Transport ProteinsGeneral Medicinemedicine.diseaseGastrointestinal MicrobiomeMicroRNAs030104 developmental biologyCardiovascular agent030211 gastroenterology & hepatologyChemical and Drug Induced Liver InjurybusinessFood ScienceHealthcare systemFood and Chemical Toxicology
researchProduct

2020

Skeletal muscle injuries in competitive sports cause lengthy absences of athletes from tournaments. This is of tremendous competitive and economic relevance for both the athletes and their respective clubs. Therapy for structural muscle lesions aims to promote regeneration and fast-track return-to-play. A common clinical treatment strategy for muscle injuries is the intramuscular injection of calf blood compound and the homeopathic drug, Tr14. Although the combination of these two agents was reported to reduce recovery time, the regulatory mechanism whereby this occurs remains unknown. In this in vivo study, we selected a rat model of mechanical muscle injury to investigate the effect of th…

0301 basic medicineDrugmedicine.medical_specialtyCombination therapySports medicinemedia_common.quotation_subjectPharmacologyCatalysisInorganic Chemistry03 medical and health sciences0302 clinical medicineIn vivoGene expressionMedicinePhysical and Theoretical ChemistryMolecular BiologySpectroscopymedia_commonbusiness.industryRegeneration (biology)Organic ChemistrySkeletal muscle030229 sport sciencesGeneral MedicineComputer Science Applications030104 developmental biologymedicine.anatomical_structurebusinessIntramuscular injectionInternational Journal of Molecular Sciences
researchProduct

Bisphosphonates, vitamin D, parathyroid hormone, and osteonecrosis of the jaw. Could there be a missing link?

2016

It is estimated that over 190 million bisphosphonates have been prescribed worldwide. But this drug can produce adverse effects, of which osteonecrosis of the jaw and severe hypocalcemia are the most serious. It is evident that bisphosphonate administration affects multiple and diverse biochemical mediators related to bone metabolism. This review of literature investigates four basic parameters in patients treated with bisphosphonates - parathyroid hormone (PTH), bisphosphonates, vitamin D, calcium, and jaw osteonecrosis - which are fundamental for assessing bone metabolism and so the efficacy and correct use of the drug. The imbalances generated by vitamin D and calcium deficiencies, toget…

0301 basic medicineDrugmedicine.medical_specialtymedia_common.quotation_subjectmedicine.medical_treatmentParathyroid hormoneOdontologíaReviewBioinformaticsBone remodeling03 medical and health sciences0302 clinical medicineInternal medicineVitamin D and neurologyHumansMedicineVitamin DAdverse effectGeneral Dentistrymedia_commonBisphosphonate-associated osteonecrosis of the jawDiphosphonatesbusiness.industry030206 dentistryBisphosphonate:CIENCIAS MÉDICAS [UNESCO]medicine.diseaseCiencias de la salud030104 developmental biologyEndocrinologyOtorhinolaryngologyParathyroid HormoneUNESCO::CIENCIAS MÉDICASBisphosphonate-Associated Osteonecrosis of the JawSurgeryOral SurgerybusinessOsteonecrosis of the jawMedicina Oral Patología Oral y Cirugia Bucal
researchProduct

Identification of NF-κB as Determinant of Posttraumatic Stress Disorder and Its Inhibition by the Chinese Herbal Remedy Free and Easy Wanderer

2017

Posttraumatic stress disorder (PTSD) is a mental disorder developing after exposure to traumatic events. Although psychotherapy reveals some therapeutic effectiveness, clinically sustainable cure is still uncertain. Some Chinese herbal formulae are reported to work well clinically against mental diseases in Asian countries, but the safety and their mode of action are still unclear. In this study, we investigated the mechanisms of Chinese remedy free and easy wanderer (FAEW) on PTSD. We used a reverse pharmacology approach combining clinical data to search for mechanisms of PTSD with subsequent in vitro verification and bioinformatics techniques as follows: (1) by analyzing microarray-based …

0301 basic medicineDrugmedicine.medical_specialtypharmacognosyMicroarraymedia_common.quotation_subjectPharmacologyNF-κB03 medical and health scienceschemistry.chemical_compoundIn vivofree and easy wanderermedicinePharmacology (medical)PsychiatryMode of actionOriginal Researchmedia_commonPharmacologyFluoxetineReverse pharmacologybusiness.industryPaeoniflorin030104 developmental biologychemistryinflammationposttraumatic stress disorderAntidepressantbusinessmedicine.drugFrontiers in Pharmacology
researchProduct

Drug Retention Rate and Predictive Factors of Drug Survival for Interleukin-1 Inhibitors in Systemic Juvenile Idiopathic Arthritis.

2019

Introduction: The advent of biologic agents has revolutionized therapeutic approaches in systemic juvenile idiopatic arthritis (sJIA) as their introduction has been shown to modify disease course and improve overall outcomes, particularly when initiated early. Few studies have reported the drug retention rate (DRR) of biologic drugs in JIA, and none of them has specifically investigated the DRR of interleukin (IL)-1 inhibitors on sJIA. Objectives: The primary aim of the study was to examine the overall DRR of IL-1 blockers in sJIA patients. Secondary aims of our study were to: (i) explore the influence of biologic line of treatment, adverse events (AEs), type of anti-IL-1 agent and the conc…

0301 basic medicineDrugmedicine.medical_specialtysystemic juvenile idiopathic arthritismedia_common.quotation_subjectArthritisanakinra; canakinumab; drug retention rate; interleukin 1-beta; systemic juvenile idiopathic arthritis; therapycanakinumab03 medical and health sciencesSettore MED/38 - Pediatria Generale E Specialistica0302 clinical medicineInterleukin-1 inhibitors Systemic Juvenile Idiopathic Arthritis Anakinra CanakinumabInternal medicineinterleukin 1-betaMedicinePharmacology (medical)Adverse effectmedia_commonOriginal ResearchPharmacologyAnakinraAnakinra Canakinumab Drug retention rate Interleukin 1-beta Systemic juvenile idiopathic arthritis Therapytherapybusiness.industrylcsh:RM1-950Hazard ratioInterleukinJuvenile idiopathic arthritisRetention ratemedicine.diseaseCanakinumablcsh:Therapeutics. Pharmacology030104 developmental biology030220 oncology & carcinogenesisSystemic juvenile idiopathic arthritidrug retention ratebusinessmedicine.druganakinraFrontiers in pharmacology
researchProduct